Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
45results about How to "Reduce dissociation" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cross-Linked Biopolymers, Related Compounds and Methods of Use
ActiveUS20110027394A1Improve physical stabilityIncrease rangeAntibacterial agentsBiocidePersonal careCross-link
The present invention provides stabilized oil-in-water emulsions with an extended range of chemical, thermal and / or mechanical stabilities, and method(s) for their preparation. Such preparations provide an environmentally-protective biopolymer component exhibiting improved adherence to the dispersed phase, reducing or eliminating dissociation therefrom under such conditions, for use in the context of a range of food, pharmaceutical, personal care, health care, cosmetic and other end-use applications.
Owner:UNIV OF MASSACHUSETTS
Stabilized human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using same
ActiveUS20140302080A1Reduce dissociationImprove stabilitySugar derivativesViral antigen ingredientsImmunodeficiency virusHuman immunodeficiency
The invention features stabilized human immunodeficiency virus (HIV) envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and / or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Ground crosslinked acid crosslinking agent and preparation method thereof
ActiveCN103484097AIncrease the number ofReduce the numberDrilling compositionHigh concentrationAcid fracturing
The invention discloses a ground crosslinked acid crosslinking agent and a preparation method thereof. The crosslinking agent comprises 5-20% of zirconium oxychloride, 10-50% of a low molecular alcohol, 5-25% of alpha-hydroxy carboxylic acid, 5-25% of a polyol, 0.1-2.0% of a polyhydroxy carboxylate and the balance of water. The preparation method comprises dissolving the 5-20% of zirconium oxychloride in the balance of water, adding the low molecular alcohol, letting in nitrogen, heating up to 50-60 DEG C, reacting for 1.5h-2h, stopping nitrogen, adding the 5-25% of alpha-hydroxy carboxylic acid, the 5-25% of polyol and the 0.1-2% of polyhydroxy carboxylate, continuing to react for 1.5h-2h at 50-55 DEG C, neutralizing a reaction product to pH for 3-5 to obtain the crosslinking agent. The crosslinking agent can crosslink acrylamide polymers in an acid liquid with a high concentration to obtain acid containing gel with high viscosity, and is especially suitable for oilfield reservoir acid fracturing of 100-150 DEG C.
Owner:CHINA PETROLEUM & CHEM CORP +1
Use of supported nano zinc oxide as anti-diarrhea agent for weaned pigs and using method
InactiveCN102335196AAvoid uneven loadGood dispersionInorganic active ingredientsDigestive systemSide effectFeces
The invention discloses use of supported nano zinc oxide as an anti-diarrhea agent for weaned pigs and a using method. According to the use of the supported nano zinc oxide as the anti-diarrhea agent for the weaned pigs, the supported nano zinc oxide is a composite material for supporting nano zinc oxide by using kaolin or montmorillonite or attapulgite or sepiolite or zeolite as a supporter. The zinc oxide accounts for 10 to 50 weight percent of the composite material for supporting the nano zinc oxide. The using method of the supported nano zinc oxide serving as the anti-diarrhea agent for the weaned pigs comprises that 160 to 800 mg / kg of supported nano zinc oxide based on zinc is added into a weaned pig feed. The supported nano zinc oxide can remarkably reduce the diarrhea rate of the weaned pigs, improve the daily gain, improve the form of the intestinal mucous membrane and protect the intestinal mucous membrane barrier; the fur of the pigs is red and bright; the toxic or side effect of high-zinc daily ration on the pigs is avoided; and the effect of the supported nano zinc oxide exceeds that of high-dose common zinc oxide, the consumption of the zinc oxide is greatly reduced, and zinc excretion and environmental pollution are reduced.
Owner:ZHEJIANG UNIV
Gastroretentive pharmaceutical dosage form
InactiveUS20110182988A1Reduce dissociationGreat hydrogen bondBiocidePeptide/protein ingredientsAdjuvantSufficient time
This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.
Owner:UNIVERSITY OF THE WITWATERSRAND
Multi-unit gastroretentive pharmaceutical dosage form comprising microparticles
This invention relates to an orally administrable, gastroretentive pharmaceutical dosage form which contains at least one pharmaceutically active ingredient and at least one polymeric adjuvant. The adjuvant serves to retain the dosage form in a selected region of the gastrointestinal tract for sufficient time for the pharmaceutically active ingredient to be released and absorbed. Ideally the dosage form will contain two or more pharmaceutically active ingredients which are delivered to different regions of the gastrointestinal tract.
Owner:UNIVERSITY OF THE WITWATERSRAND
Anode active material compsns anode sheet and Li ion cell
ActiveCN1835262AReduce dissociationImprove collection efficiencyElectrode manufacturing processesLithium compoundsLarge capacityMix proportion
The secondary battery of lithium ion includes positive pole, negative pole, electrolyte and diaphragm. The active material of positive pole is prepared by mixing spinel type lithium manganate and ternary positive materials of nickel, manganese and cobalt according to proportion 1-9: 9-1. Controlling mixing proportion and mean grain sizes of the said two substances controls orientation of spinel type lithium manganate on ternary positive materials as well as restrains Yang-Taylor effect of spinel type lithium manganate by ternary positive materials. The invention produces non-aqueous secondary battery of lithium ion with features of low cost, high capacity, good thermal stability, and good discharge performance of large current and small attenuation of capacity under high temperature.
Owner:HUZHOU CHUANGYA POWER BATTERY MATERIALS
Plasma etching method
ActiveUS20050101137A1Easy to shapeHigh selectivityElectric discharge tubesSemiconductor/solid-state device manufacturingReactive gasCompound (substance)
A plasma etching is performed on a substrate having a pattern wherein an interval between neighboring openings formed on a resist mask is equal to or less than 200 nm, wherein the etching is performed by converting a processing gas comprising an active species generating gas which includes a compound having carbon and fluorine, and a nonreactive gas which includes xenon gas into a plasma. The nonreactive gas further includes argon gas.
Owner:TOKYO ELECTRON LTD
Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers
ActiveUS9932370B2Reduce dissociationImprove stabilityViral antigen ingredientsVirus peptidesImmunodeficiency virusAmino acid
The invention features isolated human immunodeficiency virus (HIV) envelope (Env) trimers, in which the amino acid sequence of the Env polypeptides is optimized to stabilize formation of the trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and / or facilitate production of the stabilized HIV Env trimers. In addition, the invention features methods of making and using the stabilized HIV Env trimers of the invention.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Type 1 ryanodine receptor-based methods
InactiveUS7312044B2Avoid dissociationReduce dissociationCompounds screening/testingOrganic active ingredientsRyanodine receptorSkeletal muscle
This invention provides methods of treating defective skeletal muscle function during heart failure and methods for identifying compounds useful in such treatments.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Soluble CTLA4 mutant molecules and uses thereof
InactiveCN101255192AReduce dissociationHigh affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsSolubilityDiamino acid
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and / or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Owner:BRISTOL MYERS SQUIBB CO
Preparation method of functionalized graphene and application of functionalized graphene in formaldehyde adsorption
InactiveCN107138130ALarge specific surface areaImprove adsorption capacityGas treatmentOther chemical processesSurface reactionDecomposition
The invention belongs to the technical field of adsorption. Graphene is subjected to functional modification by virtue of ammonia water and hydrazine hydrate, and meanwhile, the surface of graphene is uniformly adhered with titanium dioxide when graphene is subjected to ultrasonic dispersion. In a formaldehyde adsorption process, on one hand, amino groups on the surface of graphene react with formaldehyde, and on the other hand, the decomposition of formaldehyde can be promoted by titanium dioxide, so that the phenomenon that formaldehyde dissociates after being adsorbed is remarkably reduced by virtue of a synergistic effect of the amino groups and formaldehyde.
Owner:常州城工新材料科技有限公司
Methods for identifying compounds
PendingUS20200143903A1High confidence predictionPoint to optimizationPeptide librariesMolecular designData setVirtual screening
The present disclosure provides virtual screening methods utilizing data sets from nucleotide-encoded libraries (e.g., DNA-encoded libraries). These methods allow for high confidence predictions of binding interactions between candidate compounds and proteins of interest useful for the development of therapeutics.
Owner:X CHEM
CxNy/BiVO4 material for photoanode and preparation method and application thereof
ActiveCN111364080AEnvironmentally friendlyOvercome expensiveElectrolytic inorganic material coatingMaterial electrochemical variablesElectron holeThiourea
The invention relates to a CxNy / BiVO4 material for a photoanode and a preparation method and application thereof, and belongs to the technical field of preparation of photoanode materials. The preparation method comprises the following steps that a mixture of dicyandiamide and thiourea is calcined in a muffle furnace to obtain bulk-phase carbon nitride; then the bulk-phase carbon nitride is dispersed in deionized water, and transferred into a hydrothermal reactor to be kept in a certain temperature for a certain time to obtain carbon nitride hydrogel; then electrochemical deposition and subsequent annealing treatment is used for obtaining a nano-porous BiVO4 electrode; and the carbon nitride hydrogel is dripped on the BiVO4 electrode for annealing treatment to obtain a CxNy / BiVO4 photoanode. According to the CxNy / BiVO4 photoanode, the proper interfacial charge distribution is beneficial to the separation of photon-generated carriers in the CxNy / BiVO4 interface region, so that the recombination of electron-hole pairs is reduced.
Owner:CHINA ACADEMY OF SPACE TECHNOLOGY
Preparation method of soil remediation material
InactiveCN109880629AImprove adsorption capacityReduce dissociationAgriculture tools and machinesOrganic fertilisersBiological activationSilica gel
The invention relates to the field of soil remediation and relates to a preparation method of a soil remediation material. According to the invention, after natural attapulgite clay is subjected to acid treatment, impurities such as dolomite and calcium carbonate are removed, the bonding force between original molecules is weakened, pore channels are dredged, uniformly-distributed gaps are formedon the surface, the adsorption performance of the soil remediation material is improved, activation pore channels are provided for the load of nano zero-valent iron, polyethyleneimine is tightly adsorbed on the inner surface of silica gel pores to form a nanofiltration film, heavy metal ions can be adsorbed and concentrated, the heavy metal ions can be efficiently adsorbed, the zero-valent iron can increase the effective surface area of nano-particles and enhance the active sites, and the electron transfer is enhanced, so that the adsorption efficiency is improved, the zero-valent iron can exchange heavy metals in the soil after being oxidized, after ferrous ions are fixed by Rhodococcus coprophilus, metabolic channels are induced to change, more degradable soil organic pollutants can be secreted, and the method has a wide application prospect.
Owner:雷小鹏
Anti-immune complex antibodies
InactiveUS20130231462A1Reduce dissociationExtend your lifeImmunoglobulinsImmune complex depositionPrimary and secondary antibodies
Provided are methods and compositions for immunoassays with improved sensitivity and specificity. The presently disclosed anti-immune complex antibodies stabilize the interaction between a primary and secondary antibody, thereby allowing for more stringent wash conditions, less background, and stronger signal.
Owner:BIO RAD LAB INC
Bioactive conjugate, preparation method therefor and use thereof
PendingUS20200347075A1Improve couplingCouple efficiency be highPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsMoietyDisease
The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
Stabilized human immunodeficiency virus (HIV) clade c envelope (ENV) trimer vaccines and methods of using same
ActiveUS20160243215A1Reduce levelIncrease levelAntibody mimetics/scaffoldsViral antigen ingredientsImmunodeficiency virusHuman immunodeficiency
The invention features stabilized human immunodeficiency virus (H IV) clade C envelope (Env) trimers. The invention also features vaccines, nucleic acids, and vectors to deliver and / or facilitate production of the stabilized HIV clade C Env trimers. In addition, the invention features methods of making and using the stabilized HIV clade C Env trimers of the invention.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC
Quantum dot ligand exchange method
InactiveCN112011328AExtend your lifeImprove carrier conductivitySolid-state devicesSemiconductor/solid-state device manufacturingCombinatorial chemistryOrganic chemistry
The invention provides a quantum dot ligand exchange method which comprises the following steps: dissolving quantum dots of which the surfaces are combined with oil-soluble organic ligands in a non-polar solvent to prepare a quantum dot solution; dissolving an inorganic ligand in a polar solvent to prepare an inorganic ligand solution; mixing the quantum dot solution and the inorganic ligand solution and then evenly mixing so that quantum dots in the quantum dot solution are transferred into the inorganic ligand solution on the lower layer, inorganic ligands in the inorganic ligand solution are combined with the quantum dots, and the quantum dots with the surfaces combined with the inorganic ligands are obtained.
Owner:TCL CORPORATION
Bioactive conjugate, preparation method therefor and use thereof
PendingUS20210101906A2Way of increaseImprove stabilityPeptide/protein ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsDiseasePharmaceutical drug
The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.
Owner:SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD
Catalyst and process of upgrading heavy oil in the presence of steam
ActiveUS20210189261A1Alleviates water dissociationFacilitate of oxygen radicalCatalytic crackingRefining by heating/coolingPtru catalystEmulsion
Embodiments of the disclosure provide an aqueous reforming system and a method for upgrading heavy hydrocarbons. A hydrocarbon feed and a surfactant stream are combined to produce a first precursor stream. The first precursor stream and an alkali feed are combined to produce a second precursor stream. The second precursor stream and a transition metal feed are combined to produce a catalytic emulsion stream. The catalytic emulsion stream is heated to produce a catalytic suspension and a decomposition gas, where the decomposition gas is separated by a first separator. The catalytic suspension is combined with a preheated water stream to produce an aqueous reformer feed. The aqueous reformer feed is introduced to an aqueous reformer such that the heavy hydrocarbons undergo conversion reactions to produce an effluent stream. The effluent stream is introduced to a second separator to produce a heavy stream and a light stream. The light stream is introduced to a third separator to produce a gas stream, a distillate stream, and a spent water stream. Optionally, a portion of the distillate stream and the hydrocarbon feed can be combined to produce the first precursor stream such that the first precursor stream is in the absence of a surfactant.
Owner:SAUDI ARABIAN OIL CO
Signature-based human immunodeficiency virus (HIV) envelope (ENV) trimer vaccines and methods of using the same
ActiveUS20200055901A1Reduce riskReduce deliveryViral antigen ingredientsVirus peptidesImmunogenicityPolynucleotide
The invention features immunogenic compositions and vaccines containing an optimized human immunodeficiency virus (HIV) envelope (Env) polypeptide (e.g., a stabilized trimer of optimized HIV Env polypeptides) or a polynucleotide encoding an optimized HIV Env polypeptide and uses thereof. The invention also features methods of treating and / or preventing a HIV infection by administering an immunogenic composition or vaccine of the invention to a subject (e.g., a human).
Owner:TRIAD NAT SECURITY LLC +1
Inhibitors of cyclin dependent kinase 7 (CDK7)
ActiveUS11311542B2Easy to solveImprove efficacyOrganic active ingredientsNervous disorderDiseasePathologic Angiogenesis
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and / or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and / or inhibit the transcription of disease-related genes in the patient (or in a biological sample).
Owner:SYROS PHARMACEUTICALIS INC
Colla corii asini peptide-iron chelate microcapsule and preparation method thereof
PendingCN114651989AMitigation of dissociationImprove biological accessibilityFood homogenisationFood shapingProtein proteinColla corii asini
The invention relates to a donkey-hide gelatin peptide-iron chelate microcapsule and a preparation method thereof, and relates to the technical field of microcapsules. The preparation method of the colla corii asini peptide-iron chelate microcapsule comprises the following steps: adding vegetable oil and a protein solution into the colla corii asini peptide-iron chelate for homogenizing, then adding a vegetable gelatin solution, embedding for 10-50 minutes at the rotating speed of 800-1000r / min, and then pre-cooling and freeze-drying to obtain the colla corii asini peptide-iron chelate microcapsule, the wall-core ratio of the microcapsule is (0.3-3): 1; the mass ratio of the protein to the vegetable gum is (3-7): 5. According to the microcapsule disclosed by the invention, the rust taste of an original iron agent of the donkey-hide gelatin peptide-iron chelate is improved, the stability is improved, and the micro-structure of the donkey-hide gelatin peptide-iron chelate is changed into a spherical compact structure of the microcapsule from a flaky loose porous structure of a core material in a micro-encapsulation process, so that the slow-release effect of a microcapsule product is more obvious; the biological accessibility is higher, the obvious blood replenishing effect is achieved, and the obvious technical effect is achieved.
Owner:JIANGNAN UNIV
Feed additive for prolonging storage period of fresh eggs
InactiveCN111631313AImprove antioxidant capacityBroad antioxidant activityFood processingAnimal feeding stuffBiotechnologyMicroorganism
The invention provides a feed additive for prolonging the storage period of fresh eggs. The feed additive is used for being added into a basic feed, and the feed additive comprises the following components in parts by weight: 10-30 parts of tea polyphenol, 10-30 parts of curcumin, 20-70 parts of diglucose selenite and 20-70 parts of a carrier, wherein the carrier comprises bentonite and rice branand husk, and the weight ratio of the bentonite to the rice bran and husk is (1:1)-(3:1). In each ton of basic feed, the dosage of the feed additive is 400-600g. After the feed additive disclosed by the invention is added into basic feed for use, oxidation resistance and antibacterial ability of fresh eggs are greatly improved, growth and propagation of microorganisms are inhibited, the mildewingand rotting quantity of the fresh eggs is reduced, and the storage period of the fresh eggs is prolonged. The feed additive disclosed by the invention is non-toxic and harmless to a human body, has the effects of scavenging free radicals in the body, resisting oxidation and resisting aging, and is beneficial to human health.
Owner:湖南省畜牧兽医研究所
Plasma etching method
ActiveUS7300881B2Widening of an upper portion of a recess can be suppressedHigh selectivityElectric discharge tubesSemiconductor/solid-state device manufacturingResistReactive gas
A plasma etching is performed on a substrate having a pattern wherein an interval between neighboring openings formed on a resist mask is equal to or less than 200 nm, wherein the etching is performed by converting a processing gas comprising an active species generating gas which includes a compound having carbon and fluorine, and a nonreactive gas which includes xenon gas into a plasma. The nonreactive gas further includes argon gas.
Owner:TOKYO ELECTRON LTD
Process for paper-making method remade tobacco leaves airflow tobacco shred drying
The invention belongs to the technical field of tobacco processing, and particularly relates to a process for paper-making method remade tobacco leaves airflow tobacco shred drying. The process for the paper-making method remade tobacco leaves airflow tobacco shred drying comprises the following steps: resurgence and airflow drying are conducted to remade tobacco leaves after being cut into shreds, and a moisture content of the tobacco shreds is controlled to 23-25%. The process for the paper-making method remade tobacco leaves airflow tobacco shred drying has the advantages of greatly reducing an attrition rate of the paper-making method tobacco leaves in a tobacco shred drying procedure, greatly improving effective utilization, increasing padding values of finished tobacco shreds, improving whole tobacco shred rate, reducing broken tobacco shred rate and tar yield of finished cigarettes, improving cigarette formula integrity, and enabling cigarette sensory quality to be close to a design value.
Owner:CHINA TOBACCO HENAN IND
Soluble CTL A4 mutant molecules and use thereof
InactiveCN1309735CReduce dissociationHigh affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsSolubilityDiamino acid
The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and / or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
Owner:BRISTOL MYERS SQUIBB CO
Shelf stable, brewed beverage concentrates and methods of making the same
InactiveCN103917100ANot easy to releaseLower pHTea extractionTea flavoringWater contentGeneral Appearance
Liquid brewed beverage concentrates and methods of making the concentrates are provided herein. The concentrates are liquid and flowable at room temperature and can be diluted in an aqueous liquid to provide a beverage having the general appearance, flavor, and aroma of a freshly brewed beverage. The concentrates include a low water content, high non-aqueous liquid content, particularly non-volatile non-aqueous liquid content, and high flavor solids content, the amounts of which are balanced to provide concentrates with a desired flavor profile with little or no flavor degradation after storage at room temperature in a sealed container for at least about three months.
Owner:KRAFT FOODS GRP BRANDS LLC
High-efficiency cyclone sorting preparer
Owner:TANGSHAN BRANCH COAL SCI ACAD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com